JP2005525790A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525790A5
JP2005525790A5 JP2003545261A JP2003545261A JP2005525790A5 JP 2005525790 A5 JP2005525790 A5 JP 2005525790A5 JP 2003545261 A JP2003545261 A JP 2003545261A JP 2003545261 A JP2003545261 A JP 2003545261A JP 2005525790 A5 JP2005525790 A5 JP 2005525790A5
Authority
JP
Japan
Prior art keywords
protein
disease
expression
activity
rnai construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525790A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/037146 external-priority patent/WO2003043580A2/en
Publication of JP2005525790A publication Critical patent/JP2005525790A/ja
Publication of JP2005525790A5 publication Critical patent/JP2005525790A5/ja
Pending legal-status Critical Current

Links

JP2003545261A 2001-11-19 2002-11-19 潜在的薬物ターゲットを同定及びバリデートする方法 Pending JP2005525790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33170101P 2001-11-19 2001-11-19
PCT/US2002/037146 WO2003043580A2 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets

Publications (2)

Publication Number Publication Date
JP2005525790A JP2005525790A (ja) 2005-09-02
JP2005525790A5 true JP2005525790A5 (https=) 2006-01-12

Family

ID=23295003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545261A Pending JP2005525790A (ja) 2001-11-19 2002-11-19 潜在的薬物ターゲットを同定及びバリデートする方法

Country Status (7)

Country Link
US (1) US20030194725A1 (https=)
EP (1) EP1456647A4 (https=)
JP (1) JP2005525790A (https=)
AU (1) AU2002352797A1 (https=)
CA (1) CA2468107A1 (https=)
IL (1) IL162062A0 (https=)
WO (1) WO2003043580A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049607A1 (en) * 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
CN1926551B (zh) * 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
EP2044247A4 (en) * 2006-07-11 2010-07-21 Avalon Pharmaceuticals CHEMIO-SELECTIVE IDENTIFICATION OF THERAPEUTIC PRODUCTS
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6278039B1 (en) * 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
CA2308582A1 (en) * 1997-11-06 1999-05-20 Fred Hutchinson Cancer Research Center Method for identifying drug targets
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000008181A2 (en) * 1998-08-07 2000-02-17 Onyx Pharmaceuticals, Inc. Chp polypeptide, a ligand of pak65
AU767507B2 (en) * 1998-08-28 2003-11-13 New York University Novel ubiquitin ligases as therapeutic targets
AU6158799A (en) * 1998-10-13 2000-05-01 Onyx Pharmaceuticals, Inc. Novel cell signaling polypeptides and nucleic acids
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
CA2362520A1 (en) * 1999-02-26 2000-08-31 Joan W. Conaway Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
EP1988165A1 (en) * 1999-03-31 2008-11-05 The University of North Carolina at Chapel Hill Isolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same
AU6611900A (en) * 1999-07-30 2001-03-13 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6610489B2 (en) * 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
EP1442062A4 (en) * 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA

Similar Documents

Publication Publication Date Title
Zhang et al. ISGylation in innate antiviral immunity and pathogen defense responses: a review
Kumar et al. CRISPR-Cas system: an approach with potentials for COVID-19 diagnosis and therapeutics
Carnero et al. Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication
Diray-Arce et al. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
US9662314B2 (en) Compounds and methods for the treatment of muscular disease, and related screening methods
US20130323835A1 (en) Mammalian Genes Involved in Infection
Davenport et al. Transcriptomic profiling facilitates classification of response to influenza challenge
Smits et al. High prevalence of anelloviruses in vitreous fluid of children with seasonal hyperacute panuveitis
Zeballos C et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins
Xing et al. Exploration of biomarkers of psoriasis through combined multiomics analysis
Molès et al. A new endogenous retroviral sequence is expressed in skin of patients with psoriasis
Liu et al. Non-coding RNAs expression in SARS-CoV-2 infection: Pathogenesis, clinical significance and therapeutic targets
Zhang et al. Identification of cuproptosis and immune-related gene prognostic signature in lung adenocarcinoma
Gangadharan et al. Murine gammaherpesvirus-induced fibrosis is associated with the development of alternatively activated macrophages
Li et al. Genotype-specific precision tumor therapy using mitochondrial DNA mutation-induced drug release system
Dai et al. Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation
Kubota et al. Evaluation of the effect of gene duplication by genome editing on drug resistance in Plasmodium falciparum
Tepper et al. FIT-PNAs as RNA-sensing probes for drug-resistant Plasmodium falciparum
JP2005525790A5 (https=)
Rasmussen et al. Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques
Li et al. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9
Lamers et al. HIV-associated neuropathogenesis: a systems biology perspective for modeling and therapy
Wünnemann et al. CRISPR perturbations at many coronary artery disease loci impair vascular endothelial cell functions
Panda et al. An update on cerebral malaria for therapeutic intervention
Bekkar et al. Dissection of the macrophage response towards infection by the Leishmania-viral endosymbiont duo and dynamics of the type I interferon response